Evidence map›Paper›PMID 39081883›Full record

ArticleFrontiers in microbiology2024

Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing

Cristiana Leanza, Maria Teresa Mascellino, Lorenzo Volpicelli, Sara Covino, Antonio Falletta, Francesca Cancelli, Cristiana Franchi, Martina Carnevalini, Claudio M Mastroianni, Alessandra Oliva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Effectiveness of imipenem-relebactam for multidrug-resistantAntimicrobial agents and chemotherapy · 2025
    Observational
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Review
  11. Difficult-to-TreatAntibiotics (Basel, Switzerland) · 2025
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cristiana LeanzaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Maria Teresa MascellinoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Lorenzo VolpicelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Sara CovinoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Antonio FallettaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Francesca CancelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Cristiana FranchiAOU Policlinico Umberto I, Rome, Italy.
Martina CarnevaliniAOU Policlinico Umberto I, Rome, Italy.
Claudio M MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Alessandra OlivaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Real-life experience with imipenem/cilastatin/relebactam (IMI/REL) for the treatment of KPC-producing Methods: Adult patients with KPC-Kp or DTR-PA infections who received ≥48 h of IMI/REL were included. Clinical and microbiological outcomes were retrieved through the medical records. Primary outcome was clinical cure. Secondary outcomes included mortality from infection onset and adverse effects attributable to IMI/REL. Results: We included 10 patients with different infections caused by DTR-PA ( Discussion: We reported the preliminary real-life experience on the successful and safe use of IMI/REL for the treatment of KPC-Kp or DTR-PA complicated infections, including pneumonia and bone infections.

Indexed as

antimicrobial resistanceceftazidime-avibactam resistanceimipenem/cilastatin/relebactamimipenem-relebactamKPC-producing Klebsiella pneumoniaeKPC variantpolymicrobial infections

Identifiers

PMID39081883
PMCPMC11286388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.